Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of recombinant human prourokinase vs alteplase for acute STEMI thrombolysis
ChiCTR2600119388Phase 3Not yet recruiting
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of suramin in myocardial infarction (MI) (2 arms), sponsored by General Hospital of the Northern Theater Command. Primary endpoint: Patency rate of the infarct-related artery by coronary angiography at 90–180 minutes. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
suramin
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on ChiCTR2600119388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119388.